Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation

(2017) Mohanad H. Nada et al.   Journal for ImmunoTherapy of Cancer

Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug

(2017) Yoshimasa Tanaka et al.   Scientific Reports

T cells for viral infections after allogeneic hematopoietic stem cell transplant

(2016) Catherine M. Bollard et al.   BLOOD

Targeting Cancer Cells with a Bisphosphonate Prodrug

(2016) Kenji Matsumoto et al.   ChemMedChem

Prospects for gene-engineered T cell immunotherapy for solid cancers

(2016) Christopher A Klebanoff et al.   NATURE MEDICINE

Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells

(2015) Hong Wang et al.   JOURNAL OF IMMUNOLOGY

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Insoluble drug delivery strategies: review of recent advances and business prospects

(2015) Sandeep Kalepu et al.   Acta Pharmaceutica Sinica B

The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells

(2014) Andrew Sandstrom et al.   IMMUNITY

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer

(2014) Ikuo Wada et al.   Cancer Medicine

Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain

(2013) Takamichi Izumi et al.   CYTOTHERAPY

Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human V 2V 2 T Cells

(2013) H. Wang et al.   JOURNAL OF IMMUNOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human    T-cell subset

(2012) C. Harly et al.   BLOOD

The Molecular Basis for Modulation of Human Vγ9Vδ2 T Cell Responses by CD277/Butyrophilin-3 (BTN3A)-specific Antibodies

(2012) Aparna Palakodeti et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype

(2012) Niwa Ali et al.   PLoS One

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

(2011) A J Nicol et al.   BRITISH JOURNAL OF CANCER

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

(2011) Hirohito Kobayashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indirect Stimulation of Human Vγ2Vδ2 T Cells through Alterations in Isoprenoid Metabolism

(2011) Hong Wang et al.   JOURNAL OF IMMUNOLOGY

Adoptive Immunotherapy for Advanced Non-small CellLung Cancer Using Zoledronate-expanded γδTCells

(2011) Miki Sakamoto et al.   JOURNAL OF IMMUNOTHERAPY

Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors

(2010) Atsutaka Noguchi et al.   CYTOTHERAPY

Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens

(2010) Masashi Iwasaki et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

Highly Sensitive Model for Xenogenic GVHD Using Severe Immunodeficient NOG Mice

(2009) Ryoji Ito et al.   TRANSPLANTATION

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY